S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (23rd June 2022)

• Record Type: Journal Article
• Authors: Dekhtiarenko, I.; Lelios, I.; Attig, J.; Sleiman, N.; Lazzaro, D.; Clausen, I.; Gräfe, N.; Helms, H.-J.; Schindler, E.; Belli, S.; Fauti, T.; Eckmann, J.; Umana, P.; Jacob, W.; Schneider, M.; Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; Koh, Y; Manier, S.; Facon, T.; Harrison, S. J.; Er, J.; Volzone, F.; Pinto, A.; Montes, C.; Ocio, E. M.; Alfonso-Pierola, A.; Rodríguez Otero, P.; Offner, F.; Guidetti, A.; Corradini, P.; Titouan, C.; Hulin, C.; Touzeau, C.; Moreau, P.; Popat, R.; Leong, S.; Mazza, R.; Carlo-Stella, C.; Bröske, A.-M. E.;
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 74
• Page End: 75
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000843584.56113.c6
• Languages: English
• ISSNs: 2572-9241